BR112022014493A2 - Célula de cho que expressa heterodímeros de il-15 - Google Patents
Célula de cho que expressa heterodímeros de il-15Info
- Publication number
- BR112022014493A2 BR112022014493A2 BR112022014493A BR112022014493A BR112022014493A2 BR 112022014493 A2 BR112022014493 A2 BR 112022014493A2 BR 112022014493 A BR112022014493 A BR 112022014493A BR 112022014493 A BR112022014493 A BR 112022014493A BR 112022014493 A2 BR112022014493 A2 BR 112022014493A2
- Authority
- BR
- Brazil
- Prior art keywords
- cho cell
- heterodimers
- cell expressing
- heterodimer
- producing
- Prior art date
Links
- 239000000833 heterodimer Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
CÉLULA DE CHO QUE EXPRESSA HETERODÍMEROS DE IL-15. A presente invenção refere-se ao heterodímero de IL-15/IL-15Ra produzido em uma linhagem de célula de CHO e método para produzir o heterodímero e método de tratamento com o uso do heterodímero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062970485P | 2020-02-05 | 2020-02-05 | |
PCT/IB2021/050730 WO2021156720A1 (en) | 2020-02-05 | 2021-01-29 | Cho cell expressing il-15 heterodimers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022014493A2 true BR112022014493A2 (pt) | 2022-09-20 |
Family
ID=74554194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022014493A BR112022014493A2 (pt) | 2020-02-05 | 2021-01-29 | Célula de cho que expressa heterodímeros de il-15 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20210244821A1 (pt) |
EP (1) | EP4100425A1 (pt) |
JP (2) | JP2022522566A (pt) |
KR (1) | KR20220137651A (pt) |
CN (1) | CN115023436A (pt) |
AR (1) | AR121261A1 (pt) |
AU (1) | AU2021215893A1 (pt) |
BR (1) | BR112022014493A2 (pt) |
CA (1) | CA3168469A1 (pt) |
CL (2) | CL2022002094A1 (pt) |
CO (1) | CO2022010860A2 (pt) |
CR (1) | CR20220367A (pt) |
DO (1) | DOP2022000156A (pt) |
EC (1) | ECSP22060286A (pt) |
IL (1) | IL295278A (pt) |
JO (1) | JOP20220174A1 (pt) |
MX (1) | MX2022009611A (pt) |
PE (1) | PE20221509A1 (pt) |
TW (1) | TW202142558A (pt) |
UY (1) | UY39062A (pt) |
WO (1) | WO2021156720A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
JP2023550880A (ja) | 2020-10-26 | 2023-12-06 | サイチューン ファーマ | 非黒色腫皮膚癌を治療するためのIL-2/IL-15Rβγアゴニスト |
WO2024097918A1 (en) | 2022-11-04 | 2024-05-10 | Novartis Ag | Nkg2d fusion protein cancer therapy |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
CA2608474C (en) | 2005-05-17 | 2019-11-12 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
US8021668B2 (en) | 2005-12-12 | 2011-09-20 | Immune Disease Institute, Inc. | Integrin alpha L I domain mutants with increased binding affinity |
EP1984505B1 (en) * | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
IL182956A0 (en) * | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
DK2388266T3 (da) | 2007-05-11 | 2014-05-26 | Altor Bioscience Corp | Fusionsmolekyler og IL-15-varianter |
CA2727953C (en) | 2008-08-22 | 2017-05-16 | Magna Seating Inc. | Disc recliner with reduced backlash |
TWI532495B (zh) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
KR102070098B1 (ko) * | 2010-09-21 | 2020-01-28 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
JP6359019B2 (ja) * | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | IL−15Rα型、IL−15Rα型を発現する細胞、ならびにIL−15RαおよびIL−15/IL−15Rα複合体の治療上の使用 |
US11512335B2 (en) | 2014-04-29 | 2022-11-29 | Novartis Ag | Vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
JP6709456B2 (ja) * | 2014-12-19 | 2020-06-17 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | インターロイキン15タンパク複合体およびそれらの用途 |
KR20190031424A (ko) * | 2015-12-18 | 2019-03-26 | 온코섹 메디컬 인코포레이티드 | 이종 단백질 발현을 위한 플라스미드 작제물 및 사용 방법 |
US20190169253A1 (en) * | 2016-08-01 | 2019-06-06 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
MX2019004681A (es) * | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
KR20190105584A (ko) * | 2017-01-20 | 2019-09-17 | 노파르티스 아게 | 암 치료를 위한 병용 요법 |
CA3090171A1 (en) * | 2018-02-02 | 2019-08-08 | Novartis Ag | Combination of sting agonist and il-15/il15-ra for the treatment of cancer |
WO2019166617A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
-
2021
- 2021-01-29 MX MX2022009611A patent/MX2022009611A/es unknown
- 2021-01-29 PE PE2022001548A patent/PE20221509A1/es unknown
- 2021-01-29 WO PCT/IB2021/050730 patent/WO2021156720A1/en active Application Filing
- 2021-01-29 BR BR112022014493A patent/BR112022014493A2/pt unknown
- 2021-01-29 CA CA3168469A patent/CA3168469A1/en active Pending
- 2021-01-29 KR KR1020227027161A patent/KR20220137651A/ko unknown
- 2021-01-29 IL IL295278A patent/IL295278A/en unknown
- 2021-01-29 AU AU2021215893A patent/AU2021215893A1/en active Pending
- 2021-01-29 US US17/161,929 patent/US20210244821A1/en active Pending
- 2021-01-29 JO JOP/2022/0174A patent/JOP20220174A1/ar unknown
- 2021-01-29 JP JP2021521343A patent/JP2022522566A/ja active Pending
- 2021-01-29 CR CR20220367A patent/CR20220367A/es unknown
- 2021-01-29 CN CN202180011146.4A patent/CN115023436A/zh active Pending
- 2021-01-29 EP EP21703555.9A patent/EP4100425A1/en active Pending
- 2021-02-02 UY UY0001039062A patent/UY39062A/es unknown
- 2021-02-03 AR ARP210100285A patent/AR121261A1/es unknown
- 2021-02-03 TW TW110104067A patent/TW202142558A/zh unknown
-
2022
- 2022-08-01 CO CONC2022/0010860A patent/CO2022010860A2/es unknown
- 2022-08-01 EC ECSENADI202260286A patent/ECSP22060286A/es unknown
- 2022-08-03 DO DO2022000156A patent/DOP2022000156A/es unknown
- 2022-08-03 CL CL2022002094A patent/CL2022002094A1/es unknown
-
2023
- 2023-07-28 JP JP2023122933A patent/JP2023145622A/ja active Pending
- 2023-08-17 CL CL2023002447A patent/CL2023002447A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021215893A1 (en) | 2022-08-25 |
CL2023002447A1 (es) | 2024-03-15 |
IL295278A (en) | 2022-10-01 |
DOP2022000156A (es) | 2022-10-16 |
TW202142558A (zh) | 2021-11-16 |
AR121261A1 (es) | 2022-05-04 |
CA3168469A1 (en) | 2021-08-12 |
MX2022009611A (es) | 2022-11-07 |
ECSP22060286A (es) | 2022-09-30 |
CN115023436A (zh) | 2022-09-06 |
EP4100425A1 (en) | 2022-12-14 |
CR20220367A (es) | 2022-08-30 |
JP2023145622A (ja) | 2023-10-11 |
JP2022522566A (ja) | 2022-04-20 |
CL2022002094A1 (es) | 2023-03-10 |
CO2022010860A2 (es) | 2022-08-19 |
US20210244821A1 (en) | 2021-08-12 |
JOP20220174A1 (ar) | 2023-01-30 |
PE20221509A1 (es) | 2022-10-04 |
UY39062A (es) | 2021-09-30 |
KR20220137651A (ko) | 2022-10-12 |
WO2021156720A1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014493A2 (pt) | Célula de cho que expressa heterodímeros de il-15 | |
AR114541A1 (es) | Constructos de anticuerpos para cldn18.2 y cd3 | |
BR112015005653A2 (pt) | Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada | |
MX2018002293A (es) | Sistemas y métodos para las llamadas variantes de alta precisión. | |
CL2011002019A1 (es) | Metodo y sistema de computador para proveer archivos fuente a un visor de documentos que opera en un computador cliente. | |
PE20160103A1 (es) | Panel de construccion que tiene una fuerza de fijacion mejorada y metodo para la elaboracion del mismo | |
BR112015019339A2 (pt) | Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico | |
BRPI0801188B8 (pt) | cimento ósseo de polimetilmetacrilato | |
BR112016015989A2 (pt) | Método para produzir dispositivos de osteossíntese, dispositivos de osteossíntese e implantes feito de material híbrido semissintético obtido por modificação estrutural dos componentes de um biomaterial marinho natural | |
BR112023018344A2 (pt) | Composições de cimento, e métodos das mesmas | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
BR112018004619A2 (pt) | vidro de segurança e método para a obtenção | |
ECSP21063501A (es) | Métodos para el control de sigatoka negra en bananas usando aceite de pongamia y sus formulaciones | |
BR112022008652A2 (pt) | Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção | |
BR112019001186A2 (pt) | método de fazer partículas em forma de haste para uso como aditivo anti-refluxo | |
ATE470878T1 (de) | Vorrichtung zur lichtproduktion und ihre anwendung zur beleuchtung sowie beleuchtetes schild | |
PH12017500729A1 (en) | Construction panel having improved fixing strenght | |
AR102232A1 (es) | Partición para una estructura de construcción con resistencia a la deformación mejorada | |
Tarasov | The Utopianism of Western Rationalism, Positivism and Utilitarianism in the Mirror of an Anthropological and Historiosophic Thought of FM Dostoevsky and VF Odoevsky | |
MX357787B (es) | Moldura que se ilumina para un vehiculo. | |
PL426644A1 (pl) | Sposób oczyszczania tynku gipsowego | |
Gaveika | UNIFIED LAWYERS EXAMINATION, FOR AND AGAINST | |
CO2023001066A2 (es) | Anticuerpos anti- αlfa-4-βeta-7 | |
BR112022027030A2 (pt) | Composição, processo e uso | |
Le Pourhiet | Dynamics of continental break-up in oblique setting: insights from 3D numerical modelling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024001697-4 PROTOCOLO 870240007338 EM 26/01/2024 16:42. |